Control | 100 μM AMPA | |
---|---|---|
No drug | 111.0 ± 11.5 | 45.1 ± 9.4 |
Calmidazolium (3 μM) | 104.0 ± 3.0 | 36.1 ± 2.0 |
Tacrolimus (0.1 μM) | 96.9 ± 16.3 | 54.3 ± 14.3 |
C-NFκB (3.1 pmol/ml) (1:10,000) | 121.3 ± 6.8 | 60.7 ± 6.8 1-150 |
Cycloheximide (3 μg/ml) | 89.2 ± 15.7 | 69.5 ± 8.0 1-150 |
N-Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (100 μM) | 88.8 ± 13.6 | 51.8 ± 13.6 |
Boc-aspartyl-(OMe)-fluoromethyl ketone (100 μM) | 101.6 ± 6.0 | 41.6 ± 4.0 |
Idebenone (1 μM) | 89.1 ± 15.1 | 50.3 ± 32.2 |
Trolox (3 μM) | 159.9 ± 21.2 | 57.3 ± 33.2 |
Phenyl-t-butyl-nitrone (500 μM) | 139 ± 10.1 | 42.5 ± 18.1 |
N,N-dimethyl-arginine (100 μM) | 115 ± 7.1 | 63.2 ± 7.1 |
N,N-dimethyl-arginine (300 μM) | 119 ± 8.1 | 80 ± 5.5 1-150 |
DEA/NO (100 μM) | 126.5 ± 6.7 | 17.5 ± 6.7# |
Values represent mean of three experiments ± S.E.M. In each experiment, four to six wells per treatment were counted. MAP-2 counts did not vary significantly across categories. Cell counts were normalized between experiments to number of MAP-2 cells per well.
↵1-150 P < 0.05 compared with no drug.
1-160 P < 0.01 compared with no drug.
1-159 AMPA concentration was 30 μM in this experiments.